Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Collaboration expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Amgen

bluebird bio

Editas Medicine

Regeneron Pharmaceuticals

Vertex Pharmaceuticals

The Food and Drug Administration will hold an advisory committee meeting for the first CRISPR/Cas9 gene-edited product candidate this week. If approved, CRISPR Therapeutics and Vertex Pharmaceuticals' sickle cell disease therapy could generate blockbuster sales figures.

Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient

Shares of genetic engineering specialist CRISPR Therapeutics (NASDAQ: CRSP ) moved up modestly on Friday as stakeholders await a final regulatory decision regarding a key therapeutic. Earlier, CRISPR generated significant scientific buzz for its exa-cel gene editing solution to address sickle cell disease.

CRSP Stock: FDA Considers Additional Review of CRISPR Therapeutics Gene Therapy

Etsy

CRISPR Therapeutics may soon launch its first approved product. The economic environment has weighed on Etsy, but recent trends show growth may be reaccelerating.

2 Fantastic Growth Stocks to Buy Hand Over Fist

Arcellx

Apogee Therapeutics Inc

Immunome

Nuvalent

Prime Medicine Inc

Vir Biotechnology

Biotechnology is the source of some of our strongest and growing revolutions. Gene technology allows us to cure incurable diseases and make miracles happen with living organisms.

7 Biotech Stocks to Get In Now Before Investors Catch On

The potential for CRISPR Therapeutics' pipeline is tremendous. However, an expected product approval may not offer the stock a huge lift.

CRISPR Therapeutics Stock: Bull vs. Bear

Intellia Therapeutics

Superstar investor Cathie Wood believes in buying innovators when they're down and holding for the long term. Her flagship fund is outperforming the S&P 500 this year.

Cathie Wood Is Buying These Top Growth Stocks -- and Both Could Make You Richer Over Time

Global X Genomics & Biotechnology ETF

Gene editing is revolutionizing how the world approaches medicine. In fact, by “simply” removing cells from the body, editing them, and reintroducing them, we could help treat sickle-cell anemia, cancers, blood disorders, blindness, cystic fibrosis, and even muscular dystrophy if all goes according to plan.

3 Gene Editing Stocks to Generate Super-Charged Gains

Superstar investor Wood looks for innovators whose products could be game changers down the road. She goes for companies that are undervalued today considering their long-term potential.

This Cathie Wood Stock Is Set to Soar 100%, Says Wall Street

Ginkgo Bioworks Holdings

There are a couple of stocks in the healthcare sector that could climb more than 100%, according to consensus estimates from Wall Street analysts. Analysts expecting CRISPR Therapeutics to launch its first drug next year think the stock could more than double from recent prices.

2 Growth Stocks That Could Double Your Money, According to Wall Street

Gene-editing stocks have gotten pummeled by the market's growing aversion to risk. Nonetheless, the field has made substantial progress of late.

2 Growth Stocks That Could Deliver Parabolic Returns in Under 5 Years

Here we discuss some reasons why investing in CRISPR Therapeutics (CRSP) stock now may turn out to be a more prudent move than ever.

Here's Why You May Invest in CRISPR Therapeutics (CRSP) Stock

CRISPR Therapeutics has upcoming catalysts and a strong cash position, making it a solid investment opportunity. The company's pipeline includes therapies for diabetes, immuno-oncology, and hemoglobinopathies, showcasing its diverse range of applications. Concerns include the lack of insider buying, regulatory approval challenges, market acceptance, and competition in the gene editing industry.

Crispr: Upcoming Catalysts, Plenty Of Cash And Strong Partnerships Make It A Buy

Cathie Wood is betting on CRISPR Therapeutics' ability to cure certain diseases through its gene editing techniques. The company is about to reach an important moment -- one that could lead to blockbuster revenue.

Cathie Wood Is Buying CRISPR Therapeutics Ahead of This Big Event. Should You?

Pfizer

AstraZeneca

Merck

Moderna

GlaxoSmithKline

Novartis

Sanofi

Scientists Katalin Karikó and Drew Weissman were awarded the Nobel prize this week for a discovery that went under the radar for many years, until it was found to hold the key to stabilising mRNA vaccines used in the fight against the Covid-19 pandemic.   The researchers own the patents to the nucleoside modification technology licensed out to drug companies such as BioNTech SE, where Karikó once worked, which developed an mRNA vaccine against Covid-19 with Pfizer Inc (NYSE:PFE), and Moderna Therapeutics Inc (NASDAQ:MRNA).

Nobel for mRNA: Which other biotech stocks might be overlooked?

Hims & Hers Health

Wall Street analysts have high expectations for two healthcare stocks with very different businesses. CRISPR Therapeutics' next-generation gene therapies could be worth billions, but they need to earn regulatory approval first.

2 Growth Stocks That Can Rocket 98% to 108% Higher, According to Wall Street

Poseida Therapeutics

In the landscape of modern medicine, a trio of biotech giants may rewrite the rules of healthcare. In a world where precision and personalization have become the holy grail of treatment, these three companies are emerging as pioneers, guiding the world into a new era of therapeutic possibilities.

Biotechnology Breakthroughs: 3 Biotech Stocks That Could Make Early Investors Rich

ARK Genomic Revolution Multi-Sector ETF

ARK Innovation ETF

Beam Therapeutics

In September, Cathie Wood and Ark Invest bought shares of Beam Therapeutics more than a dozen times. Beam Therapeutics is a clinical-stage drugmaker with a unique approach to developing new gene therapies.

Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead?

Editas Medicine and CRISPR Therapeutics are racing towards the same market. It looks like Bluebird Bio is going to be the player to beat in that market.

Better Gene Editing Stock: Editas Medicine vs. CRISPR Therapeutics

Kratos Defense & Security Solutions

Twilio

Love her or loathe her, Cathie Wood's magnetic pull on the investment world remains undiminished. Wood has uniquely curated portfolios brimming with disruptive tech firms and ambitious start-ups offering tremendous long-term upside potential.

3 Cathie Wood Stocks Set to Explode Higher

Proto Labs

Unity Software

In an era of rapid technological advancement and groundbreaking innovations, the stock market is constantly abuzz with opportunities and potential pitfalls. Amidst this ever-evolving landscape, three companies stand out as beacons of forward-thinking progress and visionary leadership.

Futurescape: Betting Big on These 3 Next-Gen Tech Stocks

Amazon

The number of stocks to choose from could feel overwhelming, but you can narrow down the possibilities by focusing on a couple of key elements. It's important to look at future prospects, the strength of product or service offerings, and potential catalysts ahead.

If I Could Only Buy 3 Stocks in 2023, I'd Pick These

Crispr is facing its make-or-break moment and, experts say, a pivotal decision in December could spark more than just beleaguered CRSP stock.

Crispr Therapeutics, And CRISPR Gene-Editing, Face Their Make-Or-Break Moment

Chewy

Chewy has a catalyst on the horizon: expansion into an international market with strong growth potential. CRISPR Therapeutics may soon reach a big milestone: the potential approval of its first product.

2 Bargain Growth Stocks to Buy Hand Over Fist

The pharmaceuticals market has taken a bit of a breather in recent weeks after an exhilarating rally earlier this year. But seasoned investors know the ups and downs are part of the natural ebb and flow of the market, and that patience and discipline are rewarded in the long-run.

Don't Miss the Boom: 3 Pharma Stocks Set to Explode Higher

Salesforce

NEXTracker Inc

Palo Alto Networks

UiPath

SoFi Technologies

Block

In the vast equities landscape, hidden gems are waiting to be unearthed. Like diamonds in the rough, these undervalued stocks possess the potential to shine brightly in an investment portfolio.

From Dust to Diamonds: 7 Undervalued Stocks With Sparkling Prospects

News for CRISPR Therapeutics Stock (CRSP)